logo
The Clue That Tracked a Butterfly Across the Atlantic Ocean

The Clue That Tracked a Butterfly Across the Atlantic Ocean

The Atlantic07-12-2024

This article was originally published by Knowable Magazine.
On a warm summer morning in Ieper, Belgium, 66-year-old Sylvain Cuvelier steps into his blooming garden with his 14-year-old granddaughter, hoping to identify and count all the fluttering butterflies. Other days, he helps scientists by netting butterfly samples. Then he records each sighting's location using GPS, logs them in his Excel database, and sometimes sends the samples to his academic colleagues, who will analyze pollen grains clinging to the insects' bodies.
Those tiny pollen grains, gathered by citizen scientists like Cuvelier, are helping researchers study a process that until now has been largely inscrutable: the migratory patterns of insects as they move around the globe over the course of multiple generations.
Using pollen, scientists have been able to identify where individual butterflies began their journeys, and even infer the events that likely triggered their migration. The knowledge may help conservationists better understand some of the effects of climate change—not only on the insects themselves, but on their migrations and the ecosystems they inhabit.
A lot of insects spend their whole life in one place. Many others migrate, like many birds do, to avoid harsh weather, to find food, or to breed. Some estimates suggest that trillions of insects migrate across the globe each year, yet scientists know little about where they go or how they get there.
Tracking insect migration is not as straightforward as tracking birds or mammals. With birds, 'you can attach a ring to the leg or use radio tracking, and it's easy to prove that they move from point A to B,' says Tomasz Suchan, a molecular ecologist at the Polish Academy of Sciences, in Krakow. But most insects are too small for these techniques to be successful.
In North America, researchers have had some success tracking monarch butterflies, known for their remarkable migration from southern Canada and the northern United States to central Mexico. In the early 1990s, the Monarch Watch citizen-science initiative began tagging butterflies around the Rocky Mountains. Over 2 million monarchs have been tagged, with more than 19,000 recoveries reported in Mexico, where monarchs congregate to roost for the winter. This has helped biologists track their migration routes.
Butterflies without such well-defined aggregations are more difficult to track, however. For example, painted lady butterflies often appear in Europe in the fall, sometimes in great abundance. 'Then they disappear, and we don't really know where they go,' says Gerard Talavera, an entomologist at the Institut Botànic de Barcelona.
Some years back, Talavera and his team realized they might be able to track the butterflies indirectly, by studying the pollen that accumulates on their bodies. Every time a butterfly visits a flower for a sip of nectar, it also picks up grains of pollen. If the researchers could identify plants from their pollen, confirm where and when the plants were blooming, and keep tracing them as the butterflies reached different geographic regions, perhaps they could trace the butterflies' overall journey. 'The method is like we put a GPS on them,' Talavera says. 'Because we cannot do that, this is the closest we can go.'
The scientists were able to test the idea in 2019, when painted ladies experienced one of their sporadic population booms. In March of that year, as swarms of the butterflies appeared in the Middle East and the Mediterranean, the citizen scientists netted butterfly samples, then preserved them in an alcohol mixture and shipped them to Talavera's lab.
There, researchers isolated the pollen grains attached to the butterflies' bodies and sequenced a particular stretch of the pollen DNA that offers a unique signature for each plant species, a process known as metabarcoding. All the while, citizen scientists kept netting butterfly samples as the population surge gradually spread through Eastern, Northern, and Western Europe over the following months, reaching southern Morocco in early November.
Analyzing pollen collected from 264 butterflies from 10 different countries in seven months, the researchers identified 398 different plants they could use to track the butterflies' movements backward through the year. From this, they found that swarms of butterflies observed in Russia, Scandinavia, and the Baltic countries were likely the offspring of butterflies originating from the surge in Arabia and the Middle East. This appears to have spread to Eastern Europe, then Scandinavia, and then to Western Europe, resulting in a noticeable population boom in the United Kingdom, France, and Spain. From there, the butterflies may have migrated to southern Morocco, likely continuing on to tropical Africa to complete their annual cycle.
The pollen record even suggested a reason painted ladies suddenly became so abundant in 2019. Butterflies collected from the eastern Mediterranean, right at the beginning of the population spike, were carrying pollen from plant species found primarily in semi-arid shrublands, grasslands, and salt marshes of northern Arabia and the Middle East. Examining satellite images, the researchers noticed that from December 2018 to April 2019, those plants experienced big boosts in growth following a period of unusually heavy rainfall. That burst of growth, the researchers speculate, may have provided ideal conditions for the butterflies to feed and breed, kicking off the population explosion and leaving a ripple effect felt by many generations.
Talavera and his team have used pollen signatures to track other butterfly movements as well. In 2013, for example, painted lady butterflies had been found resting on the northeast coast of South America, in French Guiana. Painted ladies don't normally live in South America, and it was a mystery where they had come from. A decade later, Talavera's team sampled pollen from the still-preserved butterfly bodies and found that Guiera senegalensis, a plant found only in sub-Saharan Africa, was by far the most common type of pollen attached to these butterflies.
By analyzing coastal surveys, wind patterns, pollen, and environmental conditions, they confirmed that the butterflies probably crossed the Atlantic in up to eight days' worth of continuous flight from Africa. This finding marked the first verified instance of an insect crossing the Atlantic.
'The use of pollen metabarcoding to track where each generation of butterflies comes from and how they progress through the cycle is super novel,' says Christine Merlin, a biologist at Texas A&M University and a co-author of an article on the neurobiology of butterfly migration in the Annual Review of Entomology. Because it identifies individual plant species, she notes, this method promises greater precision than the standard method, isotope-signature analysis, which tracks regional variations in the insects' chemical makeup.
Though painted ladies serve as a model system for understanding insect migration, researchers say they are confident that this method could be suited for tracking other migrating pollinators that actively visit flowers to collect nectar, including other butterflies, syrphid flies, wasps, beetles, and moths.
Tracking migration routes of insects could be of growing importance in the face of changing climate, because such insects can carry fungal diseases in addition to pollen. In fact, Suchan detected many species of fungi in some butterflies. Approximately 1,000 fungi are known to affect insects and more than 19,000 can affect crops. Thus, migrating insects could potentially spread these fungal diseases across continents, posing risks to ecosystems and economies. Talavera, Suchan, and their colleagues hope that using pollen signatures to map changing migration patterns could help predict where fungal-disease outbreaks might occur.
Cuvelier, meanwhile, hopes to continue counting butterflies with his granddaughter. Ecologists will continue to need more 'big data' to understand large-scale phenomena, he says. Without citizen scientists, he says, 'it is impossible for researchers to gather such databases.'
Besides, he adds, young people have more to learn from citizen science than just how to catch a butterfly. 'They learn about nature,' he says, 'and this fosters curiosity in the world.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Yahoo

timea day ago

  • Yahoo

Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment

Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money
Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money

Yahoo

time4 days ago

  • Yahoo

Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money

Explore the rapid expansion of the Molecular Diagnostics Point of Care market with our in-depth report. Discover how Point of Care testing is revolutionizing healthcare by reducing costs, enhancing outcomes, and tackling Anti-Microbial Resistance. With a five-year market forecast, this report is essential for understanding potential shifts in frontline test protocols. Stay informed and confident in investment decisions with all data available in Excel format. Gain expertise in your organization at no extra cost. Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to offering. Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside. Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption. With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively. Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges. For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information. As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain. Key Topics Covered: 1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 What are Molecular Diagnostics at the Point of Care?2.2 The Diagnostics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare Spending3 Instrumentation, Automation and Diagnostic Trends3.1 Instrumentation and Automation3.1.1 Traditional Automation and Centralization3.1.2 The New Automation, Decentralization and Point Of Care3.1.3 Instruments Key to Market Share3.1.4 Bioinformatics Plays a Role3.1.5 PCR Takes Command3.1.6 Next Generation Sequencing Fuels a Revolution3.1.7 NGS Impact on Pricing3.1.8 Whole Genome Sequencing, A Brave New World3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.2.1 Hospital vs. Central Lab4.3.3 Physician Office Lab's4.3.4 Physician's and POCT5 Profiles of Key MDx Companies5.1 Abbott Laboratories5.2 Abionic5.3 Accelerate Diagnostics5.4 Access Bio5.5 Ador Diagnostics5.6 ADT Biotech5.7 Akonni Biosystems5.8 Alveo Technologies5.9 Anitoa5.10 Applied BioCode5.11 Aureum Diagnostics5.12 Aus Diagnostics5.13 Autonomous Medical Devices5.14 Baebies5.15 Beckman Coulter Diagnostics (Danaher)5.16 Becton, Dickinson and Company5.17 Binx Health5.18 Biocartis5.19 BioFire Diagnostics (bioMerieux)5.20 bioMerieux Diagnostics5.21 Bio-Rad Laboratories, Inc5.22 Bosch Healthcare Solutions GmbH5.23 Cepheid (Danaher)5.24 Credo Diagnostics Biomedical5.25 Cue Health5.26 Curetis (OpGen)5.27 Detect5.28 Diagenode Diagnostics (Hologic)5.29 Diasorin S.p.A.5.30 DNAe5.31 Domus Diagnostics5.32 Enzo Biochem5.33 Eurofins Scientific5.34 Fluxergy5.35 Fusion Genomics.5.36 Genedrive5.37 Genetic Signatures5.38 GenMark Dx (Roche)5.39 Genomadix5.40 Getlabs5.41 Global Access Diagnostics5.42 Grip Molecular Technologies5.43 Hologic5.44 Immunexpress5.45 Inflammatix5.46 Invetech5.47 Iollo5.48 J&J Innovative Medicine5.49 Karius5.50 Lucira Health (Pfizer)5.51 LumiraDx5.52 Maxim Biomedical5.53 Meep5.54 Meridian Bioscience5.55 Millipore Sigma5.56 Molbio Diagnostics5.57 NanoDx5.58 Nanomix5.59 Novacyt5.60 Novel Microdevices5.61 Novus Diagnostics5.62 Nuclein5.63 OnsiteGene5.64 Operon5.65 OraSure Technologies5.66 Oxford Nanopore Technologies5.67 Panagene5.68 Prenetics5.69 Primerdesign (Novacyt)5.70 Prominex5.71 Proof Diagnostics5.72 Qiagen5.73 QuantuMDx5.74 QuidelOrtho5.75 R-Biopharm AG5.76 Response Biomedical5.77 Revvity5.78 Roche Diagnostics5.79 Salignostics5.80 SD Biosensor5.81 Seegene5.82 Sekisui Diagnostics5.83 Siemens Healthineers5.84 Sona Nanotech5.85 SpeeDx5.86 T2 Biosystems5.87 Talis Biomedical5.88 Thermo Fisher Scientific5.89 Uniogen5.90 Veramarx5.91 Veredus Laboratories5.92 XCR Diagnostics5.93 Zhejiang Orient Gene Biotech6 Market Trends6.1 Factors Driving Growth6.1.1 New Genotypes Creating New Markets6.1.2 Aging Population a Boon for All Diagnostics6.1.3 Developing World Driving ID Dx Growth6.1.4 Point of Care - Why Centralization is Losing Steam6.1.5 Self Testing6.1.6 The Need for Speed6.2 Factors Limiting Growth6.2.1 Lower Costs6.2.2 Infectious Disease is Declining6.2.3 Wellness Hurts6.2.4 Economic Growth improves Living Standards7 Molecular Dx - Infectious Disease Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform7.3 Roche receives FDA clearance for STI at POC7.4 Smartphone-Enabled Platform Transforms POC Testing7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch7.6 A low-cost CRISPR-based paper strip test for flu7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/257.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact7.11 DiagMetrics Developing Breath Assays7.12 Fortis Life Sciences Acquires IPOC7.13 Domus Diagnostics Wins NIH RADx Tech Contract7.14 Llusern Scientific to Launch POC MDx UTI Panel7.15 Altratech Enters POC MDx Testing Space with Unique Tech7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit7.20 NanoDx Prepares for Point-of-Care Commercialization7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection7.22 MicroGEM to Expand 30-Minute RT-PCR System7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument7.24 Diagnostics for the Real World Third-Generation POC Platform7.25 Salignostics Closes Funding Round7.26 Cue Health Targets DTC Market in 20227.27 Grip Molecular Developing Home Respiratory Panel7.28 Mainz Biomed Developing Home ColoAlert Assay7.29 MFB Fertility Closes Series A Financing Round7.30 Home Test Company Prenetics to go Public7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform7.33 Talis Biomedical Discusses Point-of-Care7.34 Roche to Acquire GenMark Diagnostics for $1.8B7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization7.36 Hologic to Acquire Mobidiag7.37 Lucira Health Focuses on User Friendly Approach to Home Testing7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M7.41 Mammoth Biosciences Developing Pathogen Detection Tech7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests7.43 Scanogen Developing 90 Minute Infection Test7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark7.49 Lumos Diagnostics Closes $15M Series A Funding For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money
Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money

Yahoo

time4 days ago

  • Yahoo

Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money

Explore the rapid expansion of the Molecular Diagnostics Point of Care market with our in-depth report. Discover how Point of Care testing is revolutionizing healthcare by reducing costs, enhancing outcomes, and tackling Anti-Microbial Resistance. With a five-year market forecast, this report is essential for understanding potential shifts in frontline test protocols. Stay informed and confident in investment decisions with all data available in Excel format. Gain expertise in your organization at no extra cost. Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to offering. Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside. Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption. With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively. Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges. For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information. As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain. Key Topics Covered: 1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 What are Molecular Diagnostics at the Point of Care?2.2 The Diagnostics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare Spending3 Instrumentation, Automation and Diagnostic Trends3.1 Instrumentation and Automation3.1.1 Traditional Automation and Centralization3.1.2 The New Automation, Decentralization and Point Of Care3.1.3 Instruments Key to Market Share3.1.4 Bioinformatics Plays a Role3.1.5 PCR Takes Command3.1.6 Next Generation Sequencing Fuels a Revolution3.1.7 NGS Impact on Pricing3.1.8 Whole Genome Sequencing, A Brave New World3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.2.1 Hospital vs. Central Lab4.3.3 Physician Office Lab's4.3.4 Physician's and POCT5 Profiles of Key MDx Companies5.1 Abbott Laboratories5.2 Abionic5.3 Accelerate Diagnostics5.4 Access Bio5.5 Ador Diagnostics5.6 ADT Biotech5.7 Akonni Biosystems5.8 Alveo Technologies5.9 Anitoa5.10 Applied BioCode5.11 Aureum Diagnostics5.12 Aus Diagnostics5.13 Autonomous Medical Devices5.14 Baebies5.15 Beckman Coulter Diagnostics (Danaher)5.16 Becton, Dickinson and Company5.17 Binx Health5.18 Biocartis5.19 BioFire Diagnostics (bioMerieux)5.20 bioMerieux Diagnostics5.21 Bio-Rad Laboratories, Inc5.22 Bosch Healthcare Solutions GmbH5.23 Cepheid (Danaher)5.24 Credo Diagnostics Biomedical5.25 Cue Health5.26 Curetis (OpGen)5.27 Detect5.28 Diagenode Diagnostics (Hologic)5.29 Diasorin S.p.A.5.30 DNAe5.31 Domus Diagnostics5.32 Enzo Biochem5.33 Eurofins Scientific5.34 Fluxergy5.35 Fusion Genomics.5.36 Genedrive5.37 Genetic Signatures5.38 GenMark Dx (Roche)5.39 Genomadix5.40 Getlabs5.41 Global Access Diagnostics5.42 Grip Molecular Technologies5.43 Hologic5.44 Immunexpress5.45 Inflammatix5.46 Invetech5.47 Iollo5.48 J&J Innovative Medicine5.49 Karius5.50 Lucira Health (Pfizer)5.51 LumiraDx5.52 Maxim Biomedical5.53 Meep5.54 Meridian Bioscience5.55 Millipore Sigma5.56 Molbio Diagnostics5.57 NanoDx5.58 Nanomix5.59 Novacyt5.60 Novel Microdevices5.61 Novus Diagnostics5.62 Nuclein5.63 OnsiteGene5.64 Operon5.65 OraSure Technologies5.66 Oxford Nanopore Technologies5.67 Panagene5.68 Prenetics5.69 Primerdesign (Novacyt)5.70 Prominex5.71 Proof Diagnostics5.72 Qiagen5.73 QuantuMDx5.74 QuidelOrtho5.75 R-Biopharm AG5.76 Response Biomedical5.77 Revvity5.78 Roche Diagnostics5.79 Salignostics5.80 SD Biosensor5.81 Seegene5.82 Sekisui Diagnostics5.83 Siemens Healthineers5.84 Sona Nanotech5.85 SpeeDx5.86 T2 Biosystems5.87 Talis Biomedical5.88 Thermo Fisher Scientific5.89 Uniogen5.90 Veramarx5.91 Veredus Laboratories5.92 XCR Diagnostics5.93 Zhejiang Orient Gene Biotech6 Market Trends6.1 Factors Driving Growth6.1.1 New Genotypes Creating New Markets6.1.2 Aging Population a Boon for All Diagnostics6.1.3 Developing World Driving ID Dx Growth6.1.4 Point of Care - Why Centralization is Losing Steam6.1.5 Self Testing6.1.6 The Need for Speed6.2 Factors Limiting Growth6.2.1 Lower Costs6.2.2 Infectious Disease is Declining6.2.3 Wellness Hurts6.2.4 Economic Growth improves Living Standards7 Molecular Dx - Infectious Disease Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform7.3 Roche receives FDA clearance for STI at POC7.4 Smartphone-Enabled Platform Transforms POC Testing7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch7.6 A low-cost CRISPR-based paper strip test for flu7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/257.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact7.11 DiagMetrics Developing Breath Assays7.12 Fortis Life Sciences Acquires IPOC7.13 Domus Diagnostics Wins NIH RADx Tech Contract7.14 Llusern Scientific to Launch POC MDx UTI Panel7.15 Altratech Enters POC MDx Testing Space with Unique Tech7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit7.20 NanoDx Prepares for Point-of-Care Commercialization7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection7.22 MicroGEM to Expand 30-Minute RT-PCR System7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument7.24 Diagnostics for the Real World Third-Generation POC Platform7.25 Salignostics Closes Funding Round7.26 Cue Health Targets DTC Market in 20227.27 Grip Molecular Developing Home Respiratory Panel7.28 Mainz Biomed Developing Home ColoAlert Assay7.29 MFB Fertility Closes Series A Financing Round7.30 Home Test Company Prenetics to go Public7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform7.33 Talis Biomedical Discusses Point-of-Care7.34 Roche to Acquire GenMark Diagnostics for $1.8B7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization7.36 Hologic to Acquire Mobidiag7.37 Lucira Health Focuses on User Friendly Approach to Home Testing7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M7.41 Mammoth Biosciences Developing Pathogen Detection Tech7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests7.43 Scanogen Developing 90 Minute Infection Test7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark7.49 Lumos Diagnostics Closes $15M Series A Funding For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store